S734 Etrasimod 2mg Once Daily as Treatment for Patients With Moderately to Severely Active Ulcerative Colitis: Topline and Subgroup Analysis From ELEVATE UC 52 and ELEVATE UC 12
Brian G. Feagan(Western University), Silvio Danese(IRCCS Ospedale San Raffaele), Séverine Vermeire(KU Leuven), Marla C. Dubinsky(Icahn School of Medicine at Mount Sinai), William J. Sandborn(University of San Diego), Martina Goetsch(Pfizer (United States)), Andrés Yarur(Cedars-Sinai Medical Center), Julián Panés(Hospital Clínic de Barcelona), Fabio Cataldi(Pfizer (United States)), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Christopher J. Rabbat(Abivax (France)), Geert D’Haens(Amsterdam University Medical Centers), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Michael Chiorean(Swedish Medical Center), Douglas C. Wolf(Atlanta Gastroenterology Associates), Filip Baert(AZ Delta), Timothy E. Ritter(Unknown), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Sheldon Sloan(Pfizer (United States)), Kevin Shan(Western University)
Cited by 2
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k